{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:47:32Z","timestamp":1769838452358,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["2025ZLMY-023"],"award-info":[{"award-number":["2025ZLMY-023"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02624-y","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T19:24:39Z","timestamp":1767122679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular and immune determinants of response in locally advanced deficient DNA mismatch repair\/microsatellite instability-high gastric or gastroesophageal junction adenocarcinoma treated with neoadjuvant chemoimmunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Pengfei","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingmao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangliu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zequan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengxin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengkang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yian","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"3","key":"2624_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2624_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10120-016-0601-9","volume":"20","author":"T Sano","year":"2017","unstructured":"Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: international gastric cancer association staging project. Gastric Cancer. 2017;20(2):217\u201325.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2624_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2624_CR4","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38\u201349.","journal-title":"Ann Oncol."},{"issue":"10184","key":"2624_CR5","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"key":"2624_CR6","unstructured":"AstraZeneca: Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial.; Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial.html."},{"issue":"4","key":"2624_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, Gotze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J Clin Oncol. 2024;42(4):410\u201320.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2624_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2624_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"SQ Yuan","year":"2024","unstructured":"Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30(2):552\u20139.","journal-title":"Nat Med"},{"issue":"17_suppl","key":"2624_CR10","doi-asserted-by":"publisher","first-page":"LBA5","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Cutsem EV, et al. Event-free survival (EFS) in MATTERHORN: a randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric\/gastroesophageal junction cancer (GC\/GEJC). J Clin Oncol. 2025;43(17_suppl):LBA5\u2013LBA5.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2624_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217\u201330.","journal-title":"N Engl J Med"},{"issue":"7517","key":"2624_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"2","key":"2624_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jso.23618","volume":"110","author":"YY Choi","year":"2014","unstructured":"Choi YY, Bae JM, An JY, Kwon IG, Cho I, Shin HB, et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol. 2014;110(2):129\u201335.","journal-title":"J Surg Oncol"},{"issue":"9","key":"2624_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197\u2013203.","journal-title":"JAMA Oncol"},{"issue":"35","key":"2624_CR15","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392\u2013400.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2624_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101691","volume":"45","author":"ML Tran-Minh","year":"2021","unstructured":"Tran-Minh ML, Lehmann-Che J, Lambert J, Theou-Anton N, Pote N, Dior M, et al. Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16\u201301. Clin Res Hepatol Gastroenterol. 2021;45(4):101691.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"2624_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021;7(6):895\u2013902.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2624_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"10142","key":"2624_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333.","journal-title":"Lancet"},{"issue":"10","key":"2624_CR20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"key":"2624_CR21","doi-asserted-by":"publisher","unstructured":"Al-Batran SE, Lorenzen S, Homann N, Thuss-Patience PC, Schenk M, Lindig U, et al. 1429P pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the DANTE trial of the German gastric group at the AIO and SAKK. Ann Oncol. 2021;32. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1538.","DOI":"10.1016\/j.annonc.2021.08.1538"},{"key":"2624_CR22","doi-asserted-by":"publisher","unstructured":"Riaz AA, Ginimol M, Rasha R, Ahmed K, Ahmed A, Catrin S, et al. Revised Strengthening the Reporting of Cohort, Cross-Sectional and Case-Control Studies in Surgery (STROCSS) guideline: an update for the age of artificial intelligence. Premier J Sci. 2025;2. Available from: https:\/\/doi.org\/10.70389\/pjs.100081.","DOI":"10.70389\/pjs.100081"},{"issue":"2","key":"2624_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"7","key":"2624_CR24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521\u201330.","journal-title":"Cancer"},{"issue":"15","key":"2624_CR25","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"3","key":"2624_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213\u20139.","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"2624_CR27","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"2624_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131.","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"2624_CR29","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333\u20139.","journal-title":"Bioinformatics"},{"issue":"2","key":"2624_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321-337 e10.","journal-title":"Cell."},{"issue":"16","key":"2624_CR31","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","volume":"25","author":"W Fang","year":"2019","unstructured":"Fang W, Ma Y, Yin JC, Hong S, Zhou H, Wang A, et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer. Clin Cancer Res. 2019;25(16):5015\u201326.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2624_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30(5):413\u201321.","journal-title":"Nat Biotechnol"},{"key":"2624_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1498053","volume":"2022","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Tao F, Qiu L, Chen H, Bao H, Wu X, et al. Somatic alteration characteristics of early-onset gastric cancer. J Oncol. 2022;2022:1498053.","journal-title":"J Oncol"},{"issue":"1","key":"2624_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01331-9","volume":"20","author":"W Fang","year":"2021","unstructured":"Fang W, Jin H, Zhou H, Hong S, Ma Y, Zhang Y, et al. Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. Mol Cancer. 2021;20(1):37.","journal-title":"Mol Cancer"},{"issue":"1","key":"2624_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"key":"2624_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"2624_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11(1):34.","journal-title":"Genome Med"},{"issue":"5","key":"2624_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","volume":"7","author":"D Zeng","year":"2019","unstructured":"Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7(5):737\u201350.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2624_CR39","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"7791","key":"2624_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup LM, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135.","journal-title":"Nature"},{"key":"2624_CR41","doi-asserted-by":"crossref","unstructured":"Zou Q, Wang X, Ren D, Hu B, Tang G, Zhang Y, et al. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021;9(9):e002671.","DOI":"10.1136\/jitc-2021-002671"},{"issue":"4","key":"2624_CR42","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ymeth.2010.01.005","volume":"50","author":"S Taylor","year":"2010","unstructured":"Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M. A practical approach to RT-qPCR-publishing data that conform to the MIQE guidelines. Methods. 2010;50(4):S1-5.","journal-title":"Methods"},{"issue":"20","key":"2624_CR43","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2217\/fon-2022-0093","volume":"18","author":"YY Janjigian","year":"2022","unstructured":"Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, et al. Matterhorn: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer. Future Oncol. 2022;18(20):2465\u201373.","journal-title":"Future Oncol"},{"key":"2624_CR44","doi-asserted-by":"publisher","first-page":"S1520","DOI":"10.1016\/j.annonc.2023.10.265","volume":"34","author":"DY Oh","year":"2023","unstructured":"Oh DY, Janjigian YY, Al-Batran SE, Wainberg ZA, van Cutsem E, Molena D, et al. 129O pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1520\u20131.","journal-title":"Ann Oncol"},{"issue":"2","key":"2624_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andre","year":"2023","unstructured":"Andre T, Tougeron D, Piessen G, de la Fouchardiere C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255\u201365.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"2624_CR46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","volume":"41","author":"F Pietrantonio","year":"2023","unstructured":"Pietrantonio F, Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC). J Clin Oncol. 2023;41(4_suppl):358\u2013358.","journal-title":"J Clin Oncol"},{"key":"2624_CR47","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","volume":"40","author":"Yara L Verschoor","year":"2022","unstructured":"Verschoor Yara L, van den Berg Jos\u00e9, Beets Geerard, Sikorska Karolina, Aalbers Arend, van Lent Anja, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. JCO. 2022;40:3511\u20133511.","journal-title":"JCO."},{"issue":"7216","key":"2624_CR48","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","unstructured":"Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","journal-title":"Nature"},{"issue":"1","key":"2624_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac005","volume":"4","author":"G Roman Souza","year":"2022","unstructured":"Roman Souza G, Abdalla A, Mahadevan D. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-Oncol Adv. 2022;4(1):vdac005.","journal-title":"Neuro-Oncol Adv"},{"issue":"1","key":"2624_CR50","volume":"17","author":"M Gourti","year":"2025","unstructured":"Gourti M, Makloul M, Maidi E. Managing pneumothorax in neurofibromatosis type 1: a report of a rare case. Cureus. 2025;17(1):e76983.","journal-title":"Cureus"},{"issue":"14","key":"2624_CR51","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin Cancer Res. 2021;27(14):4025\u201335.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2624_CR52","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1038\/s41598-021-99524-1","volume":"11","author":"SI Gutiontov","year":"2021","unstructured":"Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, et al. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021;11(1):20059.","journal-title":"Sci Rep"},{"issue":"5","key":"2624_CR53","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"2624_CR54","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","volume":"21","author":"T VanArsdale","year":"2015","unstructured":"VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment. Clin Cancer Res. 2015;21(13):2905\u201310.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2624_CR55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1634\/theoncologist.2016-0310","volume":"22","author":"JA Elvin","year":"2017","unstructured":"Elvin JA, Gay LM, Ort R, Shuluk J, Long J, Shelley L, et al. Clinical benefit in response to Palbociclib treatment in refractory uterine leiomyosarcomas with a common CDKN2A alteration. Oncologist. 2017;22(4):416\u201321.","journal-title":"Oncologist"},{"issue":"6","key":"2624_CR56","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","volume":"32","author":"X Gong","year":"2017","unstructured":"Gong X, Litchfield LM, Webster Y, Chio LC, Wong SS, Stewart TR, et al. Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell. 2017;32(6):761-776 e6.","journal-title":"Cancer Cell."},{"issue":"7","key":"2624_CR57","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","volume":"19","author":"R Binetruy-Tournaire","year":"2000","unstructured":"Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19(7):1525\u201333.","journal-title":"EMBO J"},{"issue":"5","key":"2624_CR58","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.devcel.2008.04.014","volume":"14","author":"M Petronczki","year":"2008","unstructured":"Petronczki M, Lenart P, Peters JM. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev Cell. 2008;14(5):646\u201359.","journal-title":"Dev Cell"},{"issue":"8","key":"2624_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrd3184","volume":"9","author":"K Strebhardt","year":"2010","unstructured":"Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010;9(8):643\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"2624_CR60","first-page":"5920","volume":"62","author":"R Neef","year":"2002","unstructured":"Neef R, Kuske MA, Prols E, Johnson JP. Identification of the human PHLDA1\/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res. 2002;62(20):5920\u20139.","journal-title":"Cancer Res"},{"issue":"9","key":"2624_CR61","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.celrep.2018.02.028","volume":"22","author":"AE Fearon","year":"2018","unstructured":"Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, et al. PHLDA1 mediates drug resistance in receptor tyrosine kinase-driven cancer. Cell Rep. 2018;22(9):2469\u201381.","journal-title":"Cell Rep"},{"key":"2624_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-015-0416-z","volume":"14","author":"MR Miller","year":"2015","unstructured":"Miller MR, Ma D, Schappet J, Breheny P, Mott SL, Bannick N, et al. Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma. Mol Cancer. 2015;14:141.","journal-title":"Mol Cancer"},{"key":"2624_CR63","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15238","volume":"11","author":"H Zhou","year":"2023","unstructured":"Zhou H, Li S, Lin Y. Prognostic significance of SH2D5 expression in lung adenocarcinoma and its relation to immune cell infiltration. PeerJ. 2023;11:e15238.","journal-title":"PeerJ"},{"issue":"10","key":"2624_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205660","volume":"13","author":"SP Verma","year":"2018","unstructured":"Verma SP, Das P. Novel splicing in IGFN1 intron 15 and role of stable G-quadruplex in the regulation of splicing in renal cell carcinoma. PLoS One. 2018;13(10):e0205660.","journal-title":"PLoS One"},{"issue":"12","key":"2624_CR65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41423-018-0007-1","volume":"15","author":"L Hong","year":"2018","unstructured":"Hong L, Li X, Zhou D, Geng J, Chen L. Role of Hippo signaling in regulating immunity. Cell Mol Immunol. 2018;15(12):1003\u20139.","journal-title":"Cell Mol Immunol"},{"key":"2624_CR66","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/srep00606","volume":"2","author":"J Wang","year":"2012","unstructured":"Wang J, Roderiquez G, Norcross MA. Control of adaptive immune responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2. Sci Rep. 2012;2:606.","journal-title":"Sci Rep"},{"key":"2624_CR67","doi-asserted-by":"crossref","unstructured":"Strickland MR, Lander EM, Gibson MK, Ilson DH, Ajani JA, Klempner SJ. Gastroesophageal adenocarcinomas with defective mismatch repair: current knowledge and clinical management. J Natl Compr Canc Netw. 2024;22(3):e237103.","DOI":"10.6004\/jnccn.2023.7103"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02624-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:03:23Z","timestamp":1769789003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02624-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2624"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02624-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Zhejiang Cancer Hospital (approval number: IRB-2022\u2013592). Written informed consent was obtained from each patient before sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SW, DW, JRY, and HB are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}